{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:56:14Z","timestamp":1792828574224,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ando.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T16:06:25Z","timestamp":1582905985000},"page":"182-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia"],"prefix":"10.1016","volume":"82","author":[{"given":"C.E.","family":"Stiles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.P.","family":"Steeds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.M.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ando.2020.02.007_bib0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ando.2020.02.007_bib0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.02.007_bib0315","series-title":"Ergot-derived dopamine agonists: risk of fibrotic reactions","author":"Medicines and Healthcare Products Regulatory Agency","year":"2008"},{"issue":"23","key":"10.1016\/j.ando.2020.02.007_bib0170","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ando.2020.02.007_bib0175","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","article-title":"3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro","volume":"63","author":"Setola","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.ando.2020.02.007_bib0180","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: an update","volume":"38","author":"Elangbam","year":"2010","journal-title":"Toxicol Pathol"},{"issue":"3","key":"10.1016\/j.ando.2020.02.007_bib0185","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2353\/ajpath.2009.081101","article-title":"Fenfluramine disrupts the mitral valve interstitial cell response to serotonin","volume":"175","author":"Connolly","year":"2009","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.ando.2020.02.007_bib0190","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1054-8807(99)00019-8","article-title":"Histologic changes in three explanted native cardiac valves following use of fenfluramines","volume":"8","author":"Steffee","year":"1999","journal-title":"Cardiovasc Pathol"},{"issue":"1","key":"10.1016\/j.ando.2020.02.007_bib0195","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7326\/0003-4819-117-1-50","article-title":"Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations","volume":"117","author":"Redfield","year":"1992","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ando.2020.02.007_bib0200","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/ejechocard\/jep023","article-title":"Role of echocardiography in toxic heart valvulopathy","volume":"10","author":"Droogmans","year":"2009","journal-title":"Eur J Echocardiogr"},{"issue":"2","key":"10.1016\/j.ando.2020.02.007_bib0205","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2018-01071","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline","volume":"104","author":"Stiles","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ando.2020.02.007_bib0210","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ando.2020.02.007_bib0215","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ando.2020.02.007_bib0220","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","article-title":"Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas","volume":"12","author":"Vallette","year":"2009","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.ando.2020.02.007_bib0225","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERP-18-0069","article-title":"Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology","volume":"6","author":"Steeds","year":"2019","journal-title":"Echo Res Pract"},{"issue":"3","key":"10.1016\/j.ando.2020.02.007_bib0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-13-0231","article-title":"Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas","volume":"169","author":"Auriemma","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ando.2020.02.007_bib0235","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1445-5994.2009.01920.x","article-title":"Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma","volume":"39","author":"Cawood","year":"2009","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.ando.2020.02.007_bib0240","first-page":"133","article-title":"A case of iatrogenic severe mitral regurgitation","volume":"80","author":"D\u2019Aloia","year":"2013","journal-title":"Monaldi Arch Chest Dis"},{"issue":"11","key":"10.1016\/j.ando.2020.02.007_bib0245","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S2213-8587(14)70212-8","article-title":"The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data","volume":"3","author":"Caputo","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ando.2020.02.007_bib0250","first-page":"797","article-title":"Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly","volume":"19","author":"Izgi","year":"2010","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.ando.2020.02.007_bib0255","first-page":"CC6","article-title":"NMDA. Severe aortic regurgitation associated with low cumulative dose cabergoline in prolactinoma: a case report","volume":"65","author":"Moore","year":"2019","journal-title":"Endocr Abstr"},{"issue":"8","key":"10.1016\/j.ando.2020.02.007_bib0260","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/js.2018-00139","article-title":"The third case of cabergoline-associated valvulopathy: the value of routine cardiovascular examination for screening","volume":"2","author":"Caputo","year":"2018","journal-title":"J Endocr Soc"},{"issue":"7","key":"10.1016\/j.ando.2020.02.007_bib0265","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/hrt.2008.163345","article-title":"Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do","volume":"95","author":"Sherlock","year":"2009","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.ando.2020.02.007_bib0270","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ando.2020.02.007_bib0275","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0002-9149(00)01008-0","article-title":"Prevalence and diagnostic value of precordial murmurs for valvular regurgitation in obese patients treated with dexfenfluramine","volume":"86","author":"Roldan","year":"2000","journal-title":"Am J Cardiol"},{"issue":"22","key":"10.1016\/j.ando.2020.02.007_bib0280","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1136\/heartjnl-2018-313082","article-title":"Cardiac auscultation poorly predicts the presence of valvular heart disease in asymptomatic primary care patients","volume":"104","author":"Gardezi","year":"2018","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.ando.2020.02.007_bib0285","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","article-title":"Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)","volume":"83","author":"Singh","year":"1999","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ando.2020.02.007_bib0290","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000360767","article-title":"Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease","volume":"99","author":"Dobson","year":"2014","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.ando.2020.02.007_bib0295","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.amjcard.2008.05.047","article-title":"Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease","volume":"102","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.ando.2020.02.007_bib0300","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1210\/jc.2016-2224","article-title":"A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline","volume":"101","author":"Drake","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ando.2020.02.007_bib0305","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1210\/jc.2019-00704","article-title":"Response to Letter to the Editor: (A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline)","volume":"104","author":"Stiles","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ando.2020.02.007_bib0310","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2265.2010.03973.x","article-title":"Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?","volume":"74","author":"Gu","year":"2011","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620300305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620300305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:53:34Z","timestamp":1757717614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426620300305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":32,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0003426620300305"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2020.02.007","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}